Hot flashes and your relationship: what partners miss, and how to start the treatment conversation

By Kevin Wolfe, Founder & CEO

Reviewed by Kindr Health Clinical Team

Published November 10, 2026 · Updated November 10, 2026

Hot flashes and night sweats can spill into sleep, mood, intimacy, and the space between partners. A Menopause survey of 253 matched U.S. couples found that 78.7% of the women (199 of 253) had never received treatment for vasomotor symptoms (VMS)—hot flashes and night sweats—even though most said they would be likely to seek care for a health condition. Partners and women also differed on how much encouragement and understanding the partner had actually provided.

The figures below come from the paper itself, not from secondary coverage. This was an online, self-reported survey (May 13–June 17, 2024) of women ages 40–65 with bothersome daily VMS and their cohabiting partners. It was funded by Astellas Pharma Inc., which markets a nonhormonal hot-flash medicine; several coauthors are Astellas employees, and medical writing was sponsor-funded. It cannot show that VMS caused the relationship changes people reported; the sample may not represent all women with hot flashes; and other factors in the sample (including mood symptoms and their treatments, and obesity) may have affected sexual-satisfaction answers. The findings can still help a couple name what is getting missed and prepare a clearer treatment conversation.

What the survey found

Women and partners were often aligned on how severe the symptoms were and how much they affected daily life. They were less aligned on support.

• Encouragement to seek care. 67.2% of partners (170 of 253) said the partner had encouraged the woman to understand her symptoms and pursue VMS treatment. Only 48.6% of the women (123 of 253) said that had happened.
• Understanding. 36.4% of partners (92 of 253) rated their own understanding of VMS as high; 14.2% of women (36 of 253) said their partner's understanding was high. The authors concluded that partners overestimated their overall support.
• Communication. In 75.1% of couples (190 of 253), both people said their satisfaction with communication about VMS was not high.
• Sexual satisfaction. Among people already in the relationship before VMS began (221 women; 224 partners), 59.3% of women (n=131) and 50.5% of partners (n=113) reported at least a two-point drop on a seven-point sexual-satisfaction scale compared with before VMS. Among those who reported any change in sexual satisfaction (153 women; 143 partners), 58.2% of women and 57.3% of partners said VMS were the primary influence. That is self-reported attribution, not a diagnosis of sexual dysfunction, and not proof of cause.

Of all 253 women, 10.7% reported prescription hormone therapy for VMS and 5.5% reported a prescription nonhormone therapy.

A partner checklist: ideas to try

These steps follow from the gaps above. They are not medical advice and not a substitute for a clinician visit.

1. Treat it as a health symptom, not a personal failing. Minimizing hot flashes as "just stress" or "just aging" is easy for a partner to miss.
2. Ask whether your encouragement is landing. Partners in this survey were more likely to believe they had encouraged treatment than women were to say they felt that encouragement. "Would it help if we looked up options together, or if I came to the visit?" beats assuming you already have.
3. Learn together, then listen. Research helps only if the next step is hearing what the symptoms feel like, without rushing to fix or dismiss them.
4. Talk about sleep and intimacy without blame. Name changes in sleep or sexual satisfaction as something you can bring to a clinician, not as a personal failing.
5. Help prepare the visit, then step back if asked. Offer to write questions or keep a simple symptom log. Medical decisions belong to the patient and the clinician.

If strain in the relationship or changes in desire persist, a clinician or a licensed therapist can help.

A visit-prep script

Change the wording so it sounds like you.

To a partner, at home:

"This isn't just stress. It's a menopause symptom, and there are treatments we can ask about. I want us on the same page, and I want to talk with a clinician about options."

To a clinician, at the visit:

"My hot flashes are affecting my sleep and my relationship. I haven't had treatment for them / I have tried ______. What are my hormonal and nonhormonal options, and which fit my age, timing, and health history? What monitoring would each one need, and how will we tell if it's helping?"

Bring how often flashes and night sweats occur, how they affect sleep and daily life, medicines you already take, and any history of blood clots, stroke, heart attack, breast cancer, liver disease, unexplained bleeding, seizures, or pregnancy potential. Options depend on your history; this script does not recommend a drug.

Treatment options, in brief

ACOG's October 2026 guidance centers shared decision-making: your symptoms, benefits and risks given your age and history, baseline risks of cardiovascular disease, breast cancer, and blood clots, and your goals.

Hormone therapy (HT) can be an important option for bothersome hot flashes when it is appropriate. If HT is chosen, ACOG recommends starting before age 60 or within 10 years of spontaneous (natural) menopause, in people without contraindications—timing for symptom care, not a claim that HT prevents heart disease, dementia, or aging.

Hormone therapy isn't right for everyone: depending on age, timing, health history and the type used, it can raise the risk of blood clots, stroke and breast cancer, and estrogen without a progestogen raises the risk of uterine cancer in people who have a uterus. History of blood clots, stroke, a current or past heart attack, breast cancer, liver disease, or unexplained vaginal bleeding is often a reason not to use systemic HT. Local vaginal treatments have different uses and risk profiles.

FDA has requested that companies remove statements about cardiovascular disease, breast cancer, and probable dementia from the boxed warning on menopausal hormone therapies, and has approved updated prescribing information for nine listed products (list current as of October 30, 2026). "Removed from the boxed warning" is not "no risks." Cardiovascular and breast cancer risk information remains in Warnings and Precautions, and the endometrial cancer boxed warning for systemic estrogen-alone products was not removed. People with a uterus who use systemic estrogen typically still need a progestogen. See what the boxed-warning changes did and didn't do.

Nonhormonal options. If hormones are not suitable or not preferred, ACOG reviews medicines including the neurokinin-receptor antagonists fezolinetant (Veozah) and elinzanetant (Lynkuet), as well as certain SSRIs and SNRIs, plus nonpharmacologic approaches such as cognitive behavioral therapy, often as adjuncts. ACOG states that evidence does not support the safety or efficacy of phytoestrogens or herbal supplements for these symptoms.

Veozah and Lynkuet are two of the newer FDA-approved nonhormonal pills for moderate to severe menopausal hot flashes. Low-dose paroxetine (Brisdelle, 7.5 mg) is also FDA-approved for these symptoms; it carries a boxed warning about suicidal thoughts and behaviors, as other SSRIs do, and has other important risks (prescribing information). These medicines are not interchangeable, and no head-to-head trial has compared Veozah and Lynkuet. A 2026 Menopause meta-analysis of seven randomized trials of neurokinin-receptor antagonists (the class that includes Veozah and Lynkuet) in 3,184 women found improved patient-reported sleep-disturbance scores versus placebo at 4, 12, and 24 weeks; the authors rated the certainty of evidence as low because of substantial unexplained heterogeneity. Better sleep scores are not the same as proving Veozah or Lynkuet treats insomnia on its own.

Veozah and Lynkuet both need safety monitoring. Veozah has a boxed warning for serious liver injury, with liver tests before starting, monthly for the first three months, and at six and nine months; it should not be used with cirrhosis, severe kidney impairment or end-stage kidney disease, or CYP1A2 inhibitor medicines. Lynkuet requires liver tests before starting and at three months; it warns about seizures and sleepiness that can impair driving, and it is contraindicated in pregnancy. These are not complete safety summaries. For the side-by-side, see our Lynkuet vs Veozah journal post. Read the labels and talk with your clinician. "Nonhormonal" does not mean "no monitoring."

Naming a medicine does not mean Kindr Health prescribes it. A licensed clinician decides based on your history.

Where Kindr fits

At Kindr Health, menopause care is clinician-led. The starting point is your symptoms, history, and goals—including how hot flashes are affecting sleep and relationships—not a one-size-fits-all recommendation. Kindr's board-certified clinicians can talk through hormonal and nonhormonal options that may fit you once enrollment opens. See Kindr Care enrollment status.

This article is for educational purposes only and is not medical advice. Talk with your clinician before starting, stopping, or changing any medication. See our medical disclaimer.

Medically reviewed by Kindr Health Clinical Team
Last updated: November 10, 2026